Relevant bibliographies by topics / Tumeur infiltrante

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Tumeur infiltrante'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tumeur infiltrante.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tumeur infiltrante"

1

Cheikh, T., S. Oukrif, A. Lakehal, et al. "Étude rétrospective de 50 patients ayant reçu une chimioradiothérapie concomitante pour une tumeur infiltrante de vessie non métastatique." Cancer/Radiothérapie 15, no. 6-7 (2011): 632. http://dx.doi.org/10.1016/j.canrad.2011.07.200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Léon, P., S. Drouin, T. Seisen, et al. "Évolution du nombre de cystectomies totales en France pour tumeur infiltrante de la vessie au cours des 10 dernières années : analyse objective des données nationales du PMSI." Progrès en Urologie 24, no. 13 (2014): 804. http://dx.doi.org/10.1016/j.purol.2014.08.048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Murphy, Christopher, Erjon Agushi, Zhangjie Su, Rainer Hinz, Federico Roncaroli, and David Coope. "Quantitative Diffusion Tensor Imaging (DTI) Analysis Reveals Different Infiltrative Patterns of Oligodendrogliomas and Astrocytomas in Peri-Tumour White Matter." Neurosurgery 84, no. 5 (2019): E273. http://dx.doi.org/10.1093/neuros/nyz001.ni2.

Full text
Abstract:
Abstract INTRODUCTION Gliomas are highly infiltrative primary brain tumours. Glioma infiltration is difficult to identify clinically using conventional diagnostic imaging. We used diffusion tensor imaging (DTI) to identify glioma infiltration in peritumour white matter (WM) and characterized differences between histological subtypes. METHODS We recruited 8 patients with a histological diagnosis of grade II or III glioma and 10 healthy controls. We compared fractional anisotropy (FA) maps of each patient against the control group using SPM8 (Matlab 2014a) to identify regions of glioma infiltration. The FA and mean diffusivity (MD) of formerly WM matter tumour regions, infiltrated WM and normal appearing WM were compared with a 2-sample t-test and characterized with respect to normal control data. RESULTS Our results have identified radiological evidence of infiltration in the peri-tumour WM of glioma patients. The infiltrated region of oligodendrogliomas extended further than that of astrocytomas. Oligodendrogliomas preferentially infiltrated larger WM tracts, whereas astrocytomas infiltrated more peripheral WM. In all grades, the 3 regions had significantly different diffusion parameters and there were significant differences between oligodendrogliomas and astrocytomas. CONCLUSION We identified previously unrecognized study wide significant changes in the peri-tumour WM of gliomas. Despite the known propensity of these tumours to infiltrate WM we found no significant DTI changes distant to the tumour. Our DTI results suggest oligodendrogliomas and astrocytomas demonstrate different infiltrative patterns, which highlights the need for astrocytomas and oligodendrogliomas to be studied separately.
APA, Harvard, Vancouver, ISO, and other styles
4

Madej, Janusz A. "Extracellular matrix in tumours as a source of additional neoplastic lesions - a review." Bulletin of the Veterinary Institute in Pulawy 58, no. 1 (2014): 1–9. http://dx.doi.org/10.2478/bvip-2014-0001.

Full text
Abstract:
AbstractThe review describes the role of cells of extracellular matrix (ECM) as a source of neoplastic outgrowths additional to the original tumour. The cells undergo a spontaneous transformation or stimulation by the original tumour through intercellular signals, e.g. through Shh protein (sonic hedgehog). Additionally, cells of an inflammatory infiltrate, which frequently accompany malignant tumours and particularly carcinomas, may regulate tumour cell behaviour. This is either by restricting tumour proliferation or, inversely, by induction and stimulation of the proliferation of another tumour cell type, e.g. mesenchymal cells. The latter type of tumour may involve formation of histologically differentiated stromal tumours (GIST), which probably originate from interstitial cells of Cajal in the alimentary tract. Occasionally, e.g. in gastric carcinoma, proliferation involves lymphoid follicles and lymphocytes of GALT (gut-associated lymphoid tissue), which gives rise to lymphoma. The process is preceded by the earlier stage of intestinal metaplasia, or is induced by gastritis alone. This is an example of primary involvement of inflammatory infiltrate cells in neoplastic progression. Despite the numerous histogenetic classifications of tumours (zygotoma benignum et zygotoma malignum, or mesenchymomata maligna et mesenchymomata benigna), currently in oncological diagnosis the view prevails that the direction of tumour differentiation and its degree of histologic malignancy (grading) are more important factors than the histogenesis of the tumour.
APA, Harvard, Vancouver, ISO, and other styles
5

Lu, Jian-Qiang, Omid Rashidipour, Beverly A. Wilson, Andrew S. Jack, Jeffrey Pugh, and Vivek Mehta. "Eosinophil Infiltrates in Pilocytic Astrocytomas of Children and Young Adults." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 41, no. 5 (2014): 632–37. http://dx.doi.org/10.1017/cjn.2014.24.

Full text
Abstract:
AbstractObjectiveEosinophils may affect each stage of tumour development. Many studies have suggested that tumour-associated tissue eosinophilia (TATE) is associated with favourable prognosis in some malignant tumours. However, only a few studies exist on TATE in central nervous system (CNS) tumours. Our recent study exhibited eosinophils in atypical teratoid/rhabdoid tumours (AT/RTs), pediatric malignant CNS tumours with divergent differentiation. This study examines eosinophils in pilocytic astrocytomas (PAs).MethodsThe study included 44 consecutive cases of patients with PAs and no concurrent CNS inflammatory disease.ResultsWe found eosinophils in 19 (43%) of 44 PAs (patient age range, 0.5-72 years). Eosinophils were intratumoural and clearly distinguishable. The density of eosinophils was rare to focally scattered. PAs containing eosinophils were located throughout the CNS. Furthermore, eosinophilic infiltration was identified in 18 (62%) of 29 pediatric (age range, 0.5-18 years) PAs but only 1 (7%) of 15 (p<0.001, significantly less) adult (age range, 20-72 years) PAs. Eosinophilic infiltration showed no significant differences between PAs with and without MRI cystic formation, surgical procedures, or PAs with and without leptomeningeal infiltration. In comparison, eosinophils were absent in 10 pediatric (age range, 0.5-15 years) ependymomas (or anaplastic ependymomas).ConclusionsThese results suggest that eosinophils are common in pediatric PAs but rare in adult PAs. This difference is probably related to the developing immune system and different tumour-specific antigens in children. TATE may play a functional role in the development of pediatric PAs, as well as some other pediatric CNS tumours such as AT/RTs.
APA, Harvard, Vancouver, ISO, and other styles
6

YASUTOMI, T., H. KOIKE, and Y. NAKATSUCHI. "Granular Cell Tumour of the Ulnar Nerve." Journal of Hand Surgery 24, no. 1 (1999): 122–24. http://dx.doi.org/10.1054/jhsb.1998.0044.

Full text
Abstract:
Although granular cell tumours have been demonstrated to have a neural origin, they rarely arise in peripheral nerve trunks. We report a case of granular cell tumour of the ulnar nerve in a 51-year-old man. Though dissectable from the nerve, this intraneural tumour showed microscopic involvement of focal nerve fibres. This tumour tended to infiltrate the nerve in the same manner as a neurofibroma.
APA, Harvard, Vancouver, ISO, and other styles
7

Nouhaud, F., M. Chakroun, C. Lenormand, et al. "Comparaison des résultats de la cystectomie radicale pour tumeurs de vessie infiltrant le muscle d’emblée vs. tumeurs de vessie secondairement infiltrantes." Progrès en Urologie 28, no. 13 (2018): 671–72. http://dx.doi.org/10.1016/j.purol.2018.07.117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Culine, S. "Chimiothérapie des tumeurs urothéliales infiltrantes." Cancer/Radiothérapie 2, no. 5 (1998): 515–20. http://dx.doi.org/10.1016/s1278-3218(98)80061-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Adhikaree, Jason, Julia Moreno-Vicente, Aanchal Preet Kaur, Andrew Mark Jackson, and Poulam M. Patel. "Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma." Cells 9, no. 2 (2020): 263. http://dx.doi.org/10.3390/cells9020263.

Full text
Abstract:
Glioblastoma (GBM) is inevitably refractory to surgery and chemoradiation. The hope for immunotherapy has yet to be realised in the treatment of GBM. Immune checkpoint blockade antibodies, particularly those targeting the Programme death 1 (PD-1)/PD-1 ligand (PD-L1) pathway, have improved the prognosis in a range of cancers. However, its use in combination with chemoradiation or as monotherapy has proved unsuccessful in treating GBM. This review focuses on our current knowledge of barriers to immunotherapy success in treating GBM, such as diminished pre-existing anti-tumour immunity represented by low levels of PD-L1 expression, low tumour mutational burden and a severely exhausted T-cell tumour infiltrate. Likewise, systemic T-cell immunosuppression is seen driven by tumoural factors and corticosteroid use. Furthermore, unique anatomical differences with primary intracranial tumours such as the blood-brain barrier, the type of antigen-presenting cells and lymphatic drainage contribute to differences in treatment success compared to extracranial tumours. There are, however, shared characteristics with those known in other tumours such as the immunosuppressive tumour microenvironment. We conclude with a summary of ongoing and future immune combination strategies in GBM, which are representative of the next wave in immuno-oncology therapeutics.
APA, Harvard, Vancouver, ISO, and other styles
10

Durdux, C., and M. Housset. "Facteurs pronostiques des tumeurs infiltrantes de vessie." Cancer/Radiothérapie 2, no. 5 (1998): 491–98. http://dx.doi.org/10.1016/s1278-3218(98)80057-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tumeur infiltrante"

1

Sahwi, Ata. "Tumeurs infiltrantes de la vessie stade pT3b : intérêt de la chimiothérapie adjuvante, à propos de 90 abservations." Montpellier 1, 1997. http://www.theses.fr/1997MON11097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lemdani, Kathia. "Optimisation de la réponse immune après traitement locorégional de tumeurs colorectales murines." Thesis, Université Paris-Saclay (ComUE), 2018. http://www.theses.fr/2018SACLS374.

Full text
Abstract:
Les métastases hépatiques compliquent l'évolution de 50% des cancers colorectaux (CCR). Plus de la moitié des patients présentent une récidive à distance avec métastases occultes pour lesquelles une chirurgie peut être réalisée dans moins de 20% des cas. L'ablation par radiofréquence (RFA) induit une réponse lymphocytaire T qui n'est pas évaluée après une intervention chirurgicale seule. L'immunothérapie combinée à la RFA pourrait potentialiser cet effet conduisant à une réponse tumorale à distance. Nous proposons une approche qui combine la RFA avec hydrogel thermoreversible libérant des agents immunomodulateurs (GMCSF et BCG) sur le site du traitementPremièrement, nous nous sommes intéressés à la sélection et à la caractérisation de la formulation optimale d’hydrogel par des techniques physicochimiques. Les propriétés de l'hydrogel ont été étudiées par rhéologie et des tests de muco-adhésion ont été mis en place. Le temps de résidence de l'hydrogel et de la protéine dans la zone tumorale a été démontré par imagerie optique. De plus, la cinétique de libération et l'intégrité du GMCSF encapsulé ont été déterminées. Ensuite, nous avons démontré l’efficacité de l’association de la RFA avec le dépôt local de l’hydrogel immunomodulatuer sur un modèle murin de cancer colorectal. En effet, nous avons observé une survie améliorée des animaux et régression complète des tumeurs distantes chez les animaux traités par la combinaison complète. Cette réponse est caractérisée par un niveau élevé de sécrétion de cytokines pro-inflammatoires par les cellules T CD4 et TCD8 et une augmentation de l’infiltrat lymphocytaire dans les tumeurs. Ceci a permis d'envisager une association avec l'immunothérapie anti-PD1 dans le traitement de macrométastases échappant au traitement combiné RFA avec l’hydrogel immunomodulateur. En effet, l’immunothérapie dans le traitement du cancer colorectal métastatique présente une efficacité limitée chez les patients. Notre travail propose a démontré que l’efficacité de l’immunomodulation locale dans l’amélioration des réponses immunitaires dans le cancer colorectal. Ces résultats permettent de reconsidérer l’utilisation de l’immunothérapie chez les patients atteints de CCR métastatique non MSI<br>Liver metastases complicate the progression of 50% of colorectal cancers (CRC). More than half of the patients have recurrent remissions with occult metastases for which surgery can be performed in less than 20% of cases. Radiofrequency ablation (RFA) induces a T lymphocyte response that is not observed after surgery alone. Combined immunotherapy with RFA may potentiate this effect leading to a distant tumor response. We propose an approach that combines RFA with thermoreversible hydrogel releasing immunomodulatory agents (GMCSF and BCG) at the treatment site.First, we focused on the selection and characterization of the optimal hydrogel formulation by physicochemical techniques. The properties of the hydrogel were studied by rheology and mucoadhesion tests were set up. The residence time of the hydrogel and the protein in the tumor zone was demonstrated by optical imaging. In addition, the release kinetics and integrity of the encapsulated GMCSF were determined. Then, we demonstrated the effectiveness of the combination of RFA with the local deposition of the immunomodulatory hydrogel on a mouse model of colorectal cancer. Indeed, we observed improved survival of animals and complete regression of distant tumors the complete treatment group. This response is characterized by a high level of pro-inflammatory cytokine secreted by CD4 and TCD8 T cells and an increase Lymphocytes infiltrating tumors. The immune escape of large lesions was reversed by association with anti-PD1 immunotherapy Indeed, immunotherapy in the treatment of metastatic colorectal cancer has limited efficacy in patients. Our work has demonstrated the effectiveness of local immunomodulation in improving immune responses in colorectal cancer. These results make it possible to reconsider the use of immunotherapy in patients with non-MSI metastatic CRC
APA, Harvard, Vancouver, ISO, and other styles
3

Lüscher, Débora. "Étude des lymphocytes T infiltrant le tissu tumoral." Master's thesis, Université Laval, 2006. http://hdl.handle.net/20.500.11794/19414.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

PATU, Vasco José Ramos Malta. "Imunohistoquímica e análise digital de imagens no carcinoma ductal infiltrante." Universidade Federal de Pernambuco, 2008. https://repositorio.ufpe.br/handle/123456789/1513.

Full text
Abstract:
Made available in DSpace on 2014-06-12T15:50:47Z (GMT). No. of bitstreams: 2 arquivo1551_1.pdf: 607060 bytes, checksum: 9365a784f9805c77a231eed4824f5685 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2008<br>Faculdade de Amparo à Ciência e Tecnologia do Estado de Pernambuco<br>A imuno-histoquímica é uma técnica de grande ajuda no diagnóstico de doenças da mama, incluindo os tumores. De igual importância, a análise digital de imagens vem sendo cada vez mais utilizada em estudos de alterações na mama. O presente estudo teve como objetivo quantificar morfometricamente a expressão do anticorpo através da imuno-histoquímica em tecidos de mama normal e o carcinoma ductal infiltrante e compará-los com a histoquímica com as lectinas Concanavalina A (Con A) e a Peanut agglutinin (PNA), todas conjugadas a peroxidase. Fragmentos cirúrgicos de tecido mamário com CDI (n = 25) foram fixados em formalina, submetidos à rotina histológica e embebidos em parafina. Foram feitos cortes histológicos (4&#956;m) montados em lâminas e corados com hematoxilina e eosina (HE) para confirmar o diagnóstico. As amostras teciduais selecionadas foram incubadas com anticorpo monoclonal anti-vimentina por uma hora em temperatura ambiente (37ºC) e então incubadas com um anticorpo secundário. A revelação foi realizada após incubação com diaminobenzidina (DAB) e peróxido de hidrogênio. Os tecidos serão desparafinizados em xilol e hidratados em álcool (70%-100%). As lâminas foram megulhadas (10 min) em 10 mM de tampão fosfato(PBS) e H2O2. Os cortes foram contracorados com hematoxilina e eosina rápida e analisados em microscópio óptico. Para controle, as ligações das lectinas foram inibidas utilizando-se methyl-&#945;-D-manosídeo para Con A e D-galactose para PNA (sigma USA). Nas 25 amostras de carcinoma ductal infiltrante foi observada a marcação de 42% dos casos para vimentina e nesses casos foi observado um aumento na marcação de PNA e diminuição da marcação com Con A. Já no restante das amostras (58%) não houve marcação para vimentina e os padrões de Con A e PNA foram invertidos em relação aos vimentina positivos. Os diferentes perfis de expressão da vimentina oferecem um ótimo suporte quantitativo para a investigação de células neoplásicas de mama
APA, Harvard, Vancouver, ISO, and other styles
5

TESSIER, MARIE-HELENE. "Immunotherapie des melanomes metastatiques par til (lymphocytes infiltrant la tumeur) : a propos de six cas." Nantes, 1993. http://www.theses.fr/1993NANT266M.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Platonova, Sophia. "Caractérisation phénotypique et fonctionnelle des cellules Natural Killer infiltrant les tumeurs pulmonaires." Paris 6, 2011. http://www.theses.fr/2011PA066561.

Full text
Abstract:
Les cellules Natural Killer (NK) ont été identifiées pour leur capacité à tuer les cellules tumorales in vitro. A ce jour, les caractéristiques fonctionnelles des cellules NK dans le microenvironnement tumoral chez l’homme sont assez peu connues. Nous avons montré que les cellules NK infiltrant les carcinomes pulmonaires non à petites cellules (NSCLC) présentent une capacité de dégranulation altérée, associée à la diminution d’expression d’un cluster de récepteurs activateurs composé de NKp30, NKp80, DNAM1 et CD16, contrairement aux cellules NK présentes dans le tissu pulmonaire non tumoral et dans le sang du même patient qui présente un profil d'expression similaire aux cellules NK du sang d'individuss sains. L'analyse de l'expression des ligands par les cellules tumorales a montré une expression hétérogène des ligands des récepteurs activateurs ou inhibiteurs. Ces résultats suggèrent une inhibition des cellules NK dans le microenvironnement tumoral
APA, Harvard, Vancouver, ISO, and other styles
7

Djenidi, Brahim Fayçal. "Caractérisation moléculaire et fonctionnelle des lymphocytes T CD8+/CD103+ infiltrant les tumeurs pulmonaires humaines." Thesis, Paris 11, 2014. http://www.theses.fr/2014PA11T044/document.

Full text
Abstract:
L’immunothérapie se présente aujourd’hui comme une alternative de choix dans le traitement des cancers. Son objectif est d’amplifier la réponse immunitaire contre les cellules tumorales tout en préservant les cellules normales. Les travaux antérieurs de mon équipe ont démontré qu'une réponse immunitaire antitumorale a lieu dans les carcinomes bronchiques non à petites cellules (CBNPC) et que des lymphocytes T cytotoxiques (CTL) spécifiques peuvent contribuer à la régression de la tumeur. Les travaux de mon équipe ont démontré aussi que l’interaction de l’intégrine CD103, souvent exprimée sur les lymphocytes infiltrant la tumeur (TIL), avec son ligand, le marqueur des cellules épithéliales E-Cadhérine, à la surface des cellules tumorales, est nécessaire à la polarisation des granules cytotoxiques et leur exocytose pour déclencher la lyse de la cellule cible. L’objectif principal de mon projet de thèse est de déterminer la contribution réelle des lymphocytes T CD8+/CD103+ infiltrant les tumeurs épithéliales dans la réponse CTL antitumorale et le rôle de CD103 dans la régulation de leurs fonctions effectrices in situ. Dans un premier temps, j’ai caractérisé, sur le plan transcriptionel et phénotypique, les TIL de CBNPC humains. Mes résultats ont montré que les lymphocytes T CD8+/CD103+ présentent une signature moléculaire caractéristique des cellules T mémoires résidentes dans les tissues (TRM), avec une expression des récepteurs CD69 et CD45RO. Mes résultats ont montré aussi que cette population lymphocytaire co-Exprime les récepteurs inhibiteurs PD-1 et Tim-3. Dans un deuxième temps, j’ai étudié la fonctionnalité des TIL CD8+/CD103+ et le rôle de CD103 dans leur activité cytotoxique anti-Tumorale. Mes résultats ont d’abord indiqué que les lymphocytes T CD103+ sont plus sensibles à la mort cellulaire induite par activation (AICD) que les TIL CD103-, et qu’ils expriment le granzyme B et CD107a suite à une activation spécifique. De plus, ils sont capables d’exercer une activité cytotoxique spécifique à l’encontre des cellules tumorales autologues suite à la neutralisation de l’interaction de PD-1 avec son PD-L1, et que des anticorps anti-CD103 bloquants inhibe cette fonction. Ensuite, j’ai analysé l’impact de l’expression de CD103 à la surface des TIL sur la survie de patients atteints de CBNPC de stade 1. Mes résultats ont révélé que cette intégrine favorise l’infiltration des TIL dans les régions tumorales épithéliales et qu’une forte expression de CD103 sur les TIL corrèle avec une amélioration de la survie des patients. Enfin, J’ai examiné le rôle de CD103 dans cette fonction et dans la réponse immunitaire antitumorale in vivo. Mes résultats préliminaires ont montré une croissance tumorale retardée des tumeurs LL2 transfectées avec l’E-Cadhérine et CCL5 greffées dans les souris CD103-WT. De plus l’inhibition de cette croissance corrèle avec une infiltration plus importante des tumeurs avec des lymphocytes T CD8+/CD103+. Ces résultats suggèrent un rôle important de la coexpression de CCL5 et d’E-Cadhérine par la tumeur dans le recrutement et la rétention des CTL au site tumoral. L’ensemble de ces travaux est en faveur du rôle important de CD103 dans la régulation de l’immunité T CD8 dans les tumeurs épithéliales et de l’utilité des anticorps neutralisants anti-PD-1 et anti-Tim-3 pour inverser l'épuisement de cette population lymphocytaires CD8+/CD103+<br>Today Immunotherapy is clearly an alternative choice in the treatment of cancers. Its main objective is to enhance the cytotoxic immune response against tumor cells while preserving normal cells. We have previously demonstrated that there is an antitumor immune response in the Non-Small-Cell lung carcinoma (NSCLC) and cytotoxic T lymphocytes (CTL) contribute to NSCLC tumor regression. We further showed that the CD103 integrin interaction (oftenly expressed on tumor infiltrating lymphocytes (TIL)) with its ligand, the epithelial cell marker E-Cadherin, expressed at the surface of tumor cells, is necessary for the polarization and exocytosis of TIL cytotoxic granules and to trigger the lysis of the tumor target cells. The main purpose of my thesis project is to determine the actual role/ contribution of CD8+/CD103+ T lymphocytes (infiltrating the epithelial tumors) in the regulation of antitumor CTL response and to study the role of CD103 in the regulation of their in situ effector functions. Firstly, TIL infiltrating human NSCLC were characterized at transcriptional and phenotypic level. My results show that CD8+/CD103+ T lymphocytes have a molecular signature characteristic of memory T cells resident in tissues (MRT), with expression of CD69 receptors and CD45RO. My results also showed that this cell population co-Expresses the inhibitory receptors, PD-1 and Tim-3.In a second step, I studied the functionality of CD8+/CD103+ TIL and the role of CD103 in the regulation of anti-Tumor cytotoxic activity. My results have first indicated that CD103+ TIL are more sensitive to activation induced cell death (AICD) than TIL-CD103- and CD103+ TIL express granzyme B and CD107a after specific activation. Furthermore, CD103+ TIL are able to exert a specific cytotoxic activity against autologous tumor cells following the neutralization of PD-1- PD-L1 interaction, and that of anti-CD103 antibody inhibits this blocking function. After, I analyzed the impact of the expression of CD103 on the surface of TIL on the survival of patients with NSCLC stage 1. My results revealed that this integrin promotes the infiltration of TIL in epithelial tumor regions and a strong expression of CD103 on TIL correlates with improved patient survival. Finally, I examined the role of CD103 in this function and the antitumor immune response in vivo. My preliminary results showed a tumor growth delay of LL2 tumors transfected with E-Cadherin and CCL5 grafted in CD103-WT mice. Furthermore inhibition of growth correlates with a higher tumor infiltrating with CD8+/CD103+ T lymphocytes. These results suggest an important role of the coexpression of CCL5 and E-Cadherin by the tumor in the recruitment and retention of CTL at the tumor site. The whole work supports the role of CD103 in regulating the CD8 T cells-Mediated immune response in epithelial tumors and the usefulness of anti-PD-1 neutralizing and anti-Tim-3 for reversing the depletion of this lymphocyte population CD8+ / CD103+
APA, Harvard, Vancouver, ISO, and other styles
8

Guerra, Nadia. "Altération de la réponse cytotoxique des lymphocytes infiltrant les tumeurs rénales : implication des récepteurs NK inhibiteurs." Paris 6, 2002. http://www.theses.fr/2002PA066166.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Khou, Sokchea. "Contribution des neutrophiles infiltrant les tumeurs dans la progression des carcinomes épidermoïdes cutanés : neutrophiles et cancer." Electronic Thesis or Diss., Université Côte d'Azur (ComUE), 2019. http://theses.univ-cotedazur.fr/2019AZUR4014.

Full text
Abstract:
Les carcinomes cutanés constituent les cancers les plus fréquents chez l’homme et leur incidence est en constante croissance. Il en existe deux principaux types : les carcinomes baso-cellulaires et les carcinomes épidermoïdes. Les facteurs de risque sont principalement l’exposition aux rayons UV et l’immunosuppression. Ils sont traités par chirurgie ou par radiothérapie mais peuvent parfois évoluer vers des formes incurables. De nouvelles alternatives thérapeutiques sont donc nécessaires. L’immunothérapie est une récente révolution dans le traitement des cancers qui vise à réactiver l’immunité des patients cancéreux. Les carcinomes cutanés pourraient en bénéficier car ils se développent lors de situations d’immunosuppression. L’immunosurveillance implique à la fois les cellules immunitaires et le microenvironnement tumoral comme le stroma. Lorsque les réponses anti-tumorales, notamment médiées par les lymphocytes T CD8+ sont efficaces, on parle de phase d’élimination. Puis vient une phase d’équilibre où la tumeur reste stable et enfin, lors de la phase finale d’échappement, des mécanismes d’immunosuppression permettent à la tumeur de croître. Les neutrophiles, des cellules immunitaires de type myéloïde, sont recrutées très rapidement aux sites d’inflammation et au sein des cancers. Une méta-analyse récente sur 39 types de cancers humains a pu associer ces cellules aux plus mauvais pronostiques cliniques. Elles sont impliquées dans des fonctions anti-tumorales et pro-tumorales. Cette polarisation semble induite respectivement par l’interféron de type I et le TGF-β. Leur rôle lors de cancers et en particulier dans les carcinomes cutanés reste encore largement incompris. Notre objectif a été de caractériser les fonctions des neutrophiles et leur contribution au développement des carcinomes épidermoïdes. Pour cela, nous avons utilisé premièrement, un modèle de carcinogénèse cutanée chimio-induite. La tumorigénèse est séquentielle et donc très représentative du carcinome cutané chez l’homme. Dans ce modèle, nous observons une infiltration massive des neutrophiles au stade précancéreux et cancéreux. Une analyse de l’expression génique des neutrophiles isolés des lésions précancéreuses et cancéreuses et des peaux environnant ces lésions a été réalisée, qui montre une signature génique spécifique des neutrophiles des lésions, comparée aux peaux environnantes. Des comparaisons d’expression génique différentielle illustrent que les neutrophiles des lésions possèdent des fonctions pro-tumorales comparés aux neutrophiles des peaux.Deuxièmement, nous avons mis en place un modèle de greffe intradermique d’une lignée de carcinome épidermoïde. Une déplétion spécifique des neutrophiles retarde significativement la croissance tumorale, ce qui confirme le caractère pro-tumoral des neutrophiles. Nous avons caractérisé les mécanismes mis en jeu, qui incluent la génération de ROS et iNOS favorisant la croissance tumorale et une suppression de l’activation et de la prolifération des lymphocytes T CD8+ anti-tumoraux. Les neutrophiles produisent de l’arginase 1 qui dégrade l’arginine et inhibe la prolifération des lymphocytes T. Par ailleurs, l’environnement tumoral induit l’expression de PD-L1 en surface des neutrophiles et de PD1 en surface des lymphocytes T CD8+ et CD4+. Ceci suggère que l’interaction PD-L1/PD1 contribue à l’immunosuppression. De plus, une corrélation positive et significative a été observée entre la taille des tumeurs et la fréquence des neutrophiles exprimant PD-L1 au sein de ces tumeurs. Au vu de ces résultats, il semble intéressant d’évaluer les immunothérapies bloquant l’interaction PD-L1/PD1 dans le traitement des carcinomes cutanés. Ces traitements pourraient être combinés avec ceux qui bloquent le recrutement ou les fonctions des neutrophiles. Il reste à évaluer si la fréquence de neutrophiles exprimant PD-L1 peut être un bon marqueur de prédiction de la réponse aux immunothérapies anti-PD-L1 ou anti-PD1<br>Non-melanoma skin carcinomas are the most frequent cancers in Human and their incidence is constantly increasing. Two main types exist: the cutaneous basal cell carcinoma (cBCC) and the cutaneous squamous cell carcinomas (cSCC). Risk factors include sun radiation and immunosuppression. These cancers are mainly treated with surgery and radiotherapy but they can reach an incurable stage. For this reason, novel therapeutic alternatives are needed. At present, immunotherapies constitute a revolution in the treatment of cancers. Its mechanism of action relies on the stimulation of the immune system of cancer patients, so that they develop efficient anti-tumoral immune responses. cSCC may benefit from this type of treatment as they generally develop in the context of an immunosuppression. Immune surveillance involves both immune cells and the tumor microenvironment, in particular the stroma. During the elimination phase, the anti-tumoral responses, mediated mainly by CD8+ T lymphocytes, are efficient. Then, there is an equilibrium phase in which the tumor is stable before the escape phase, when the tumor can evade immune surveillance and grow. Our research interest focused on neutrophils, a subset of myeloid cells that are very rapidly recruited to the sites of inflammation and inside tumors. A recent meta-analysis of 39 human malignancies showed that neutrophils are associated with the worst clinical outcome. Neutrophils harbor both anti- and pro-tumoral functions. This polarization seems to be dependent on type I interferon and TGF-β, respectively. It remains to establish the exact role played by neutrophils in cancer and specifically in skin carcinomas. The aim of our research was to further characterize the functions and the contribution of neutrophils to the development of cutaneous squamous cell carcinomas. We first used a chemically-induced skin carcinoma mouse model that recapitulates the different stages of skin carcinoma development in Human. In this model, we saw a massive infiltration of neutrophils at the precancerous and cancerous stages. We performed transcriptomic analysis of highly purified neutrophil populations from precancerous, cancerous lesions and from the surrounding skin controls. These data revealed a specific gene signature in neutrophils from lesions compared to surrounding skins. Differential gene expression analysis identified a pro-tumoral phenotype for neutrophils infiltrating lesions compared to skins. In a second approach, we studied the growth of a cSCC cell line grafted in the dermis of mice. Specific depletion of neutrophils significantly delayed tumor growth, thus indicating that neutrophils were pro-tumoral. Mechanisms of action included the production of ROS and NO that favor tumor growth and the immune suppression of anti-tumoral responses mediated by tumor-associated CD8+ T cells. In the tumor, neutrophils produced arginase 1 which catalyzes the degradation of arginine, thus inhibiting the proliferation of CD8+ T cells. In addition, we found that the tumor microenvironment induced PD-L1 expression at the cell surface of neutrophils and concomitantly, PD1 on CD8+ and CD4+ T cells. These results suggested that PD-L1/PD1 interaction triggers immune suppression and contributes to SCC progression. Indeed, a positive and significant correlation was observed between tumor size and frequencies of PD-L1-expressing neutrophils inside tumors. Collectively, these results suggest that it is relevant to assess immunotherapies that block PD-L1/PD1 interaction for the treatment for cSCC. These approaches could be combined with treatments that aim to block the recruitment or inhibit neutrophils. Moreover, it remains to evaluate whether the frequency of PD-L1-expressing neutrophils could constitute a good predictive marker of the response to anti-PD-L1 and anti-PD1 immunotherapies
APA, Harvard, Vancouver, ISO, and other styles
10

Claret, Emmanuel. "Profil de sécrétion cytokinique de clones T dérivés des lymphocytes T activés infiltrant la tumeur dans les lymphomes malins." Grenoble 1, 1992. http://www.theses.fr/1992GRE10115.

Full text
Abstract:
Plusieurs observations indiquent que les lymphocytes t infiltrant les ganglions envahis par un lymphome malin non hodgkinien b (lmnh b) ou la maladie de hodgkin (mh), sont impliques dans le processus tumoral. Afin de caracteriser les proprietes fonctionnelles de ces lymphocytes, nous avons etudie leur profil de secretion cytokinique au niveau clonal. Comme reference, des clones t ont ete obtenus a partir de situations non malignes (ganglions hyperplasiques benins (hb), sang peripherique de donneurs sains (sp)). Nous avons etudie 347 clones t (116 derives de lmnh b, 98 de mh, 95 d'hb et 38 de sp). Si la capacite de production d'il4 est restreinte a un nombre reduit de clones (37), la quasi totalite des clones etudies secrete les autres cytokines dosees. Cependant, il existe une tres grande variabilite de capacite secretrice d'un clone a l'autre. De cette diversite emergent deux groupes de clones: une population de clones produisant de faibles niveaux de cytokines que l'on retrouve dans toutes les situations malignes ou non et une population produisant de forts niveaux d'une ou plusieurs cytokines, que l'on retrouve principalement dans les ganglions malins. Dans les ganglions atteints de mh, ces clones ont une capacite de production d'il2 decrue. De part leur profil de secretion, l'on peut penser que ces lymphocytes ont un role in vivo sur le comportement de la tumeur, et particulierement dans la formation du granulome observe dans certains ganglions malins
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Tumeur infiltrante"

1

Silverstein, Melvin J., Abram Recht, and Michael D. Lagios. Ductal Carcinoma In Situ of the Breast. Lippincott Williams & Wilkins, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1940-, Silverstein Mel, Recht Abram, and Lagios Michael D, eds. Ductal carcinoma in situ of the breast. 2nd ed. Lippincott Williams & Wilkins, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Tumeur infiltrante"

1

Brusa, Davide, and Jean-Luc Balligand. "Classification of the Immune Composition in the Tumor Infiltrate." In Methods in Molecular Biology. Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9240-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bröcker, E. B., E. Macher, and C. Sorg. "Changes in the Tumor-Associated Inflammatory Infiltrates in the Course of Local and Systemic Progression of Cutaneous Melanoma." In Human Melanoma. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74496-9_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ugolkov, Andrey, and Andrew P. Mazar. "Invasion, metastasis, and tumour dormancy." In Oxford Textbook of Cancer Biology, edited by Francesco Pezzella, Mahvash Tavassoli, and David J. Kerr. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198779452.003.0019.

Full text
Abstract:
Tumours can be either benign or malignant. A first difference is that the primary malignant tumour infiltrates the surrounding tissue while, with very few exceptions, the benign tumours do not infiltrate. The second and main one is that, by definition, the malignant tumours are able to produce metastatic lesions in other organs. Finally, metastases can declare themselves even after period of years from the appearance of the first lesion. This is because of the third property of the malignant cells i.e. their ability to spread and then do not immediately grow into a detectable metastasis, but to be ‘dormant’ for a variable period.
APA, Harvard, Vancouver, ISO, and other styles
4

Basso, Cristina, Stefania Rizzo, Marialuisa Valente, Martina Perazzolo Marra, and Gaetano Thiene. "Malignant tumours, pericardial tumours, and therapy." In ESC CardioMed, edited by Gaetano Thiene. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0388.

Full text
Abstract:
Primary malignant neoplasms account for 10% of all primary cardiac tumours and are represented by sarcomas (mainly angiosarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma) and primary lymphomas. They usually infiltrate the cardiac walls, but may be also solely intracavitary, mimicking myxoma.
APA, Harvard, Vancouver, ISO, and other styles
5

"Oral problems." In Paediatric Dermatology, edited by Sue Lewis-Jones and Ruth Murphy. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198821304.003.0010.

Full text
Abstract:
The chapter demonstrates the importance of examination of the lips and oral cavity including the tongue and palate that is essential to aid accurate diagnosis and direct appropriate management. Examination may also provide clues to the recognition of systemic disorders such as Beçhet’s disease. Common oral problems like cheilitis, simple aphthous ulcers, bacterial and viral infections such as herpes simplex are described with treatment recommendations and images. Erythema multiforme, major aphthae, and recurrent aphthous stomatitis (RAS) are among the rarer diseases mentioned. Attention is also given to common tumours (lumps and bumps) such as Fox Fordyce spots, mucocoele, and viral warts and rare tumours such as leukaemic infiltrates.
APA, Harvard, Vancouver, ISO, and other styles
6

Nicolini, Fabio, and Massimiliano Mazza. "The Immune System of Mesothelioma Patients: A Window of Opportunity for Novel Immunotherapies." In Rare Diseases [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98617.

Full text
Abstract:
The interplay between the immune system and the pleural mesothelium is crucial both for the development of malignant pleural mesothelioma (MPM) and for the response of MPM patients to therapy. MPM is heavily infiltrated by several immune cell types which affect the progression of the disease. The presence of organized tertiary lymphoid structures (TLSs) witness the attempt to fight the disease in situ by adaptive immunity which is often suppressed by tumor expressed factors. In rare patients physiological, pharmacological or vaccine-induced immune response is efficient, rendering their plasma a valuable resource of anti-tumor immune cells and molecules. Of particular interest are human antibodies targeting antigens at the tumor cell surface. Here we review current knowledge regarding MPM immune infiltration, MPM immunotherapy and the harnessing of this response to identify novel biologics as biomarkers and therapeutics through innovative screening strategies.
APA, Harvard, Vancouver, ISO, and other styles
7

Baker, Ann-Marie, and Trevor A. Graham. "Concurrent in situ analysis of point mutations and immune infiltrate in FFPE cancers." In Tumor Immunology and Immunotherapy – Integrated Methods Part B. Elsevier, 2020. http://dx.doi.org/10.1016/bs.mie.2019.05.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kersten, Robert C. "Management of Periocular Neoplasms." In Surgery of the Eyelid, Lacrimal System, and Orbit. Oxford University Press, 2011. http://dx.doi.org/10.1093/oso/9780195340211.003.0007.

Full text
Abstract:
Epithelial malignancy of the eyelid is a common problem, representing about 14% of skin cancers in the head and neck region. The goals when treating any skin cancer are complete elimination of the tumor and minimal sacrifice of normal adjacent tissues. These concepts are of paramount importance when treating periocular epithelial malignancies because of the complex nature of the periocular tissues and their critical function in protecting the underlying globe, as well as the increased risk that recurrent tumor in this area poses. Many modalities have been advocated, by a variety of medical practitioners, for the treatment of epithelial malignancies in the periocular region. There are two key considerations in selecting a treatment for skin cancers. The first is that the selected modality must be capable of eradicating all tumor cells to which it is applied. The second is that some mechanism must exist to ensure that it is applied to all the existing tumor cells. Because tumors of the lid margins and canthi often exhibit slender strands and shoots of cancer cells that may infiltrate beyond the clinically apparent borders of the neoplasm, appropriate monitoring to ensure that the treatment modality reaches all of the cancer cells is essential. Numerous studies have demonstrated that clinical judgment of tumor margins is inadequate, significantly underestimating the area of microscopic tumor involvement. The introduction of frozen-section control to document adequacy of tumor excision marked a major advancement in the treatment of eyelid malignancies and now represents the standard of care. Any treatment modality that does not use microscopic monitoring of tumor margins must instead encompass a wider area of adjacent normal tissue in hopes that any microscopic extensions of tumor will fall within this area. The purpose of this chapter is to explore alternative methods of periocular cancer treatment. Mohs micrographic technique is a refinement of frozen-section control of tumor borders that, by mapping tumor planes, allows a three-dimensional evaluation of tumor margins rather than the two-dimensional examination provided by routine frozen section. The modality was initiated by Frederick E. Mohs, MD, in 1936.
APA, Harvard, Vancouver, ISO, and other styles
9

Raza, Afsheen, Maysaloun Merhi, Allan Relecom, et al. "Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer." In Advances in Precision Medicine Oncology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96494.

Full text
Abstract:
Immune checkpoint inhibitors (ICIs) have been approved as first or second line therapy in a large group of cancers. However, the observation of potentially long-lasting responses was restricted to limited subset of patients. Efforts have been made to identify predictive factors of response to ICIs in order to select eligible patients and to avoid exposing non-responding patients to treatment side effects. Although several biomarkers have been identified, their predictive potential remains unsatisfactory. One promising emerging approach is to focus on dynamic biomarkers to directly characterize the response and, more importantly, to identify those patients presenting an immune response failure. Several studies have shown a strong correlation between specific circulating immune cell subsets and tumor immune infiltrates. Moreover, liquid biomarkers including soluble immune checkpoint molecules have potential in predicting the modulation of the immune response under immune checkpoint blockade. In this chapter, we will discuss current advances in the study of circulatory and intra-tumoral dynamic biomarkers as predictors of responses to ICIs therapy in cancer.
APA, Harvard, Vancouver, ISO, and other styles
10

Araya, Romina E., and Romina S. Goldszmid. "Characterization of the tumor immune infiltrate by multiparametric flow cytometry and unbiased high-dimensional data analysis." In Methods in Enzymology. Elsevier, 2020. http://dx.doi.org/10.1016/bs.mie.2019.11.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tumeur infiltrante"

1

Tiwari, Alok, Dhananjay Gughe, Radhika Dureja, and Satinder Kaur. "Synchronous primary malignancy of ovary and cervix with different histopathology: A rare case report." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685388.

Full text
Abstract:
Concurrent different histopathological types of gynecologic tumors arise rarely. We present ovarian serous and cervical squamous cell carcinoma formed synchronously. A 51-year-old woman with a poor general condition was admitted with gradual distension of abdomen for 1 year with gradual loss of weight and appetite for the last three months and pain in the abdomen and irregular vaginal bleeding for the last two months. There was no family history of malignancy of genital tract, breast or colon. On examination she was cachexic, pale, dehydrated, tachypnoeic and had edema over feet. Per abdomen examination revealed solid, non-mobile palpable mass arising from pelvis. Per vaginal examination revealed large mass in pelvis and uterus can not be felt separately on per speculum examination there was small endocervical erosion, hypertrophied cervix. On per rectal examination bilateral parametria were free. Her tumor marker were evaluated and CA-125 was found to be raised (CA 125: 915.6 u/ml U/mL); rest tumor markers were normal. Cervical punch biopsy was suggestive of moderately differentiated carcinoma and pap smear was also suggestive of cervical cancer. MRI findings revealed a mass of altered signal intensity 2.5 × 1.5 × 2.2 cm with diffusion restriction and post contrast enhancement in the anterior lip of cervix and another large, lobulated predominantly solid mass, hypo intense on T1, intermediate on T2 with diffusion restriction and post contrast enhancement in the right adnexal region abutting the small bowel and sigmoid colon optimal debulking surgery with standard protocol was done. Histopathology report revealed squamous cell carcinoma of cervix, grade III and high grade serous cystadenocarcinoma of ovary. Tumour deposits from ovary were seen on right fallopian tube and right parametrium. Squamous cell carcinoma cervix involved ectocervix, endocervix and infiltrated near full thickness of cervical stroma, endomyometrium, vaginal cuff, paracervical tissue omentum and appendix were free of tumour. Twenty five right pelvic lymphnodes dissected were free of tumour, (00/25). One out of fifteen lymphnode dissected were involved with extra capsular extent, 01/15 and thirteen para aortic lymph node dissected were free of tumor. Immunohistochemistry markers: Ovarian mass-tumour cell expressed ck, vimentin, wt-1 with focal Ck positivity, no expression of ck20, p63, ck5/6 and CEA seen. Cervical tumour-tumour cells expressed ck, ck7, p63 and ck5/6 no expression of ck20, wt-1. Based on our case report we need to keep in mind that even if patient presents with symptoms pertaining to a single malignancy; still the rare possibility of synchronous malignancies should be looked for by doing proper investigations. In our case, patient had symptoms pertaining to ovarian malignancy; whereas cervical malignancy was diagnosed after investigating the patient. Histologic examination should be done properly as the prognosis depends on the malignancies being metastatic or synchronous one appropriate management should be offered in all such cases. Long term follow up of such patients should be maintained to determine the prognosis.
APA, Harvard, Vancouver, ISO, and other styles
2

Bruno, Tullia C., Jeffrey Kern, and Jill E. Slansky. "Abstract B39: Activated B cells infiltrate lung cancer." In Abstracts: AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; December 2-5, 2012; Miami, FL. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.tumimm2012-b39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Reiman, Derek, Lingdao Sha, Irvin Ho, Timothy Tan, Denise Lau, and Aly A. Khan. "Abstract B57: Integrating RNA expression and visual features for immune infiltrate prediction." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 27-30, 2018; Miami Beach, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm18-b57.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Figueroa, Nathania M., Brian Belt, Ankit Patel, et al. "Abstract 2951: The tumor microenvironment in cholangiocarcinoma is dominated by an immunosuppressive infiltrate." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-2951.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hubert, Margaux, Anne-Claire Doffin, Estelle Verronese, Isabelle Durand, Christophe Caux, and Jenny Valladeau-Guilemond. "Abstract A61: Human BDCA3high dendritic cells infiltrate breast and ovarian tumors but are functionally altered." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; October 20-23, 2016; Boston, MA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/2326-6074.tumimm16-a61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Truxova, Iva, Lenka Kasikova, Michal Hensler, et al. "Abstract A24: Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 17-20, 2019; Boston, MA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm19-a24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Truxova, Iva, Lenka Kasikova, Michal Hensler, et al. "Abstract B76: Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 27-30, 2018; Miami Beach, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm18-b76.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rodríguez, Cristina E., Luciana M. Moverer, Sara I. Reidel, et al. "Abstract 2881: Cytotoxic effect of trastuzumab on macrophage-infiltrated human mammary tumor spheroids." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2881.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stojdl, David. "Abstract 1473: Dual oncolytic viral immunotherapy generates large polyfunctional tumour-specific CD8 + T cell responses that infiltrate immunosuppressive tumors." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stojdl, David. "Abstract 1473: Dual oncolytic viral immunotherapy generates large polyfunctional tumour-specific CD8 + T cell responses that infiltrate immunosuppressive tumors." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tumeur infiltrante' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography